Real-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational Study
Open Access
- 1 August 2018
- journal article
- research article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 38 (9) , 853-865
Abstract
Background: There is very limited evidence examining serious systemic adverse events (SSAEs) and post-injection endophthalmitis of intravitreal bevacizumab (IVB) and intravitreal ranibizumab (IVR) treatments in Thailand and low- and middle-income countries. Moreover, findings from the existing trials might have limited generalizability to certain populations and rare SSAEs. Objectives: This prospective observational study aimed to assess and compare the safety profiles of IVB and IVR in patients with retinal diseases in Thailand. Methods: Between 2013 and 2015, 6354 patients eligible for IVB or IVR were recruited from eight hospitals. Main outcomes measures were prevalence and risk of SSAEs, mortality, and endophthalmitis during the 6-month follow-up period. Results: In the IVB and IVR groups, 94 and 6% of patients participated, respectively. The rates of outcomes in the IVB group were slightly greater than in the IVR group. All-cause mortality rates in the IVB and IVR groups were 1.10 and 0.53%, respectively. Prevalence rates of endophthalmitis and non-fatal strokes in the IVB group were 0.04% of 16,421 injections and 0.27% of 5975 patients, respectively, whereas none of these events were identified in the IVR group. There were no differences between the two groups in the risks of mortality, arteriothrombotic events (ATE), and non-fatal heart failure (HF). Adjustment for potential confounding factors and selection bias using multivariable models for time-to-event outcomes and propensity scores did not alter the results. Conclusions: The rates of SAEs in both groups were low. The IVB and IVR treatments were not associated with significant risks of mortality, ATE, and non-fatal HF. Trial Registration: Thai Clinical Trial Registry identifier TCTR20141002001.Keywords
Funding Information
- Health Systems Research Institute (57-026, 59-005)
- Royal Golden Jubilee Ph.D. Program provided by the Thailand Research Fund (TRF) and Mahidol University (PHD/0180/2554)
- Thailand Research Fund (TRF) under a grant for Senior Research Scholar (RTA5980011)
- Bill and Melinda Gates Foundation (OPP1134345)
This publication has 51 references indexed in Scilit:
- Infectious endophthalmitis: review of 420 casesClinical Ophthalmology, 2013
- The use of comparative effectiveness research to inform policy decisions on the inclusion of bevacizumab for the treatment of macular diseases in Thailand's pharmaceutical benefit packageClinicoEconomics and Outcomes Research, 2012
- A Safety Review and Meta-Analyses of Bevacizumab and Ranibizumab: Off-Label versus GoldstandardPLOS ONE, 2012
- Management of retinal vascular diseases: a patient-centric approachEye, 2012
- An Outbreak of Streptococcus Endophthalmitis After Intravitreal Injection of BevacizumabAmerican Journal of Ophthalmology, 2012
- An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational StudiesMultivariate Behavioral Research, 2011
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2011
- The Prevalence of Retinal Vein Occlusion: Pooled Data from Population Studies from the United States, Europe, Asia, and AustraliaOphthalmology, 2010
- The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwideBritish Journal of Ophthalmology, 2006
- The central role of the propensity score in observational studies for causal effectsBiometrika, 1983